Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

r of gout flares and patients receiving the 80 mg dose had a 73% decrease compared to the placebo group (p<0.0001).  

ARCALYST also met all secondary endpoints of the study.  Compared to placebo, treatment with ARCALYST reduced the proportion of patients who experienced at least one gout flare during the study period by 65% for ARCALYST 160 mg (p<0.0001) and by 60% for ARCALYST 80 mg (p=0.0002).  Compared to placebo, treatment with ARCALYST reduced the proportion of patients who experienced two or more flares by 88% for ARCALYST 160 mg (p<0.0001) and by 84% for ARCALYST 80 mg (p<0.0001).

Primary and key secondary endpoint results were as follows:PlaceboARCALYST® (rilonacept) 80 mgARCALYST® (rilonacept) 160 mg n79

80

81Primary endpointMean # of flares per patient (% reduction compared to placebo)1.06

0.29

(73% reduction)

(p<0.0001)

0.21

(80% reduction)
(p<0.0001)Key secondary endpointsProportion of patients with greater than or equal to( 1 flare (% reduction compared to placebo) 46.8%

18.8%

(60% reduction)

(p=0.0002)

16.3%

(65% reduction)

(p<0.0001)Proportion of patients with greater than or equal to( 2 flares (% reduction compared to placebo)31.6%

5.0%

(84% reduction)

(p<0.0001)

3.7%

(88% reduction)

(p<0.0001) One patient did not report flare data and was excluded from efficacy analysesOverall, the cumulative rate of infections was 17.3% in patients treated with ARCALYST 160 mg, 18.8% in patients treated with ARCALYST 80 mg, and 22.8% in placebo patients.  No deaths were reported in this study.

Specific adverse events that occurred at a frequency of at least 5% in any study group were: injection site reaction (19.8% with ARCALYST 160 mg, 8.8% with ARCALYST 80 mg, and 1.3% with placebo), upper respiratory tract infection (9.9% with ARCALYST 16
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... CGM System as a non-invasive, wireless continuous glucose ... Doman , Executive Chairman and Interim CEO of ... Capital Markets, Tenth Annual Equity Conference. ... to prospective corporate partners and investors at 9:00 ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ... as insulin delivery systems especially for type ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ... in today,s growth in the pharmaceutical industry. ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... AMSTERDAM, October 8 BMEYE B.V., the non-invasive,cardiovascular ... B financing round, raising EUR 6 million. New investors,Earlybird, ... in the,financing, along with other existing BMEYE shareholders as ... BMEYE has successfully been selling Nexfin(TM), an FDA ...
... Oct. 8 Advanced Health Media, LLC (AHM) has ... and related technology for the pharmaceutical and life sciences ... in speaker bureau management, supplying automation and compliance management ... promotional events for more than 200 brands. The ...
Cached Medicine Technology:BMEYE B.V. Completes EUR 6 Million Series B Financing Round 2BMEYE B.V. Completes EUR 6 Million Series B Financing Round 3Advanced Health Media Announces Acquisition of Ephikacy, LLC 2Advanced Health Media Announces Acquisition of Ephikacy, LLC 3
(Date:4/14/2014)... NJ. April 10, 2014. John DeLuca, PhD, and Yael ... Idec to study how persons with multiple sclerosis (MS) ... of Actual Reality to Measure Everyday Life Functional Activity ... research. Dr. DeLuca is senior VP of Research & ... at New York University, is a visiting scientist at ...
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... COLUMBUS, Ohio A new study identifies a molecule ... and suggests that the molecule could be an important ... of tumor progression. , The study of microRNA-135b (miR-135b) ... in the journal Cancer Cell and was ... Cancer Center Arthur G. James Cancer Hospital and ...
(Date:4/14/2014)... --- Depression can hit young fathers hard -- with symptoms ... their children,s lives, a new Northwestern Medicine study has found. ... the first five years of fatherhood for these young men, ... and whom lived in the same home as their children. ... the journal Pediatrics . , This study is the ...
(Date:4/14/2014)... world, many people live and work in dim and ... And as the global population continues to rise and ... spread. , To alleviate the problem, Egyptian researchers ... onto narrow streets and alleyways. The panel is mounted ... angle, where it spreads sunlight onto the street below. ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... Feb. 25 Omnicell, Inc.,(Nasdaq: OMCL ), a ... today that its Board of Directors has approved the,repurchase ... its Common Stock over,the next 12 months. The Company,s ... after a review of the Company,s financial position and,investment ...
... -- Up to 20 percent of patients taking aspirin ... event do not have an antiplatelet response from aspirin, ... at the University at Buffalo have shown. , ... of a second stroke, second heart attack or second ...
... HILL Bacteria mutate for a living, evading antibiotic drugs ... States each year. But as concern about drug-resistant bacteria grows, ... Carolina at Chapel Hill seeks to thwart the bug without ... Mark Schoenfisch and his lab of analytical chemists at UNC ...
... GmbH, a Systems Biology company focussed on high quality ... showcasing its abilities in the analysis of data generated ... Boyle et al published in the January 2008 issue ... of Open Chromatin across the Genome where they identified ...
... 25 Danaher Corporation,(NYSE: DHR ) announced ... Jr. will be presenting at the Citigroup Global ... March 5 at 8:00,a.m. EST. The audio will ... will be archived on, http://www.danaher.com for one ...
... new blockages within 3 years, study finds , , ... a blood clot in their legs (deep vein thrombosis) ... of developing another blood clot within three years, a ... embolism are known collectively as venous thromboembolism. , Researchers ...
Cached Medicine News:Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 3Health News:Many stroke, heart attack patients may not benefit from aspirin 2Health News:Many stroke, heart attack patients may not benefit from aspirin 3Health News:Silica smart bombs deliver knock-out to bacteria 2Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2Health News:Blood Clots in Legs, Lungs Predispose Patients to Repeat Episodes 2
... Technology, multi-frequency, linear micro-surgery transducer. ... very helpful in tight situations. ... a choice transducer for pediatric ... high frequency upper end makes ...
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
Super High Density, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit. Change frequencies on the fly for deeper penetration or for superficial n...
Medicine Products: